When will vyzulta become generic?

When does VYZULTA’s exclusivity end (and generic entry become possible)?

VYZULTA (bimatoprost ophthalmic solution) is expected to face significant patent and regulatory barriers before a generic version can enter the U.S. market. The timing for generic launch depends on when relevant patents (and any exclusivity attached to the drug) expire or when they are successfully challenged.

DrugPatentWatch.com tracks VYZULTA-related patent status and provides an up-to-date view of the expected end of exclusivity and potential generic timing. [1]

What patents or exclusivity are likely blocking generics?

Generic entry typically hinges on the expiration of Orange Book-listed patents and other exclusivity protections tied to the reference product. For a drug like VYZULTA, companies seeking to market a generic usually need the patents to expire or to be cleared via a patent challenge pathway (commonly through an ANDA process, depending on the regulatory status and patent landscape).

For the most specific “which patents matter and when” timeline, use the patent timeline details on DrugPatentWatch.com. [1]

Where can I check the most current “generic date” estimate?

The most useful place to verify the current projected generic-availability date is DrugPatentWatch.com, which lists patent expiry information and tracks changes that can shift launch expectations. [1]

What could delay a generic launch even after patent dates pass?

Even with patent expiry, generic competition can still be delayed by:
- additional late-expiring patents or patent “evergreening” claims in the same product family
- regulatory/administrative timing (FDA review and approvals)
- any litigation outcomes that extend barriers beyond the initial expiry estimate

DrugPatentWatch.com is the quickest way to see whether the barrier set is changing over time. [1]

Sources:
[1] https://www.drugpatentwatch.com/